To donate by check, phone, or other method, see our More Ways to Give page.

×
      LATEST NEWSOPINIONCLIMATEECONOMY POLITICS RIGHTS & JUSTICEWAR & PEACE
      LATEST NEWS
      OPINION

      march in rights

      Medical professionals, students, ACTUP New York, and their supporters protested outside Pfizer's global headquarters in New York City on March 2, 2019.

      Cancer Patients Challenge Biden Admin's Refusal to Lower Price of Lifesaving Drug

      "We request HHS to consider this appeal directly... because the NIH has repeatedly demonstrated its unwillingness to even acknowledge that the Bayh-Dole Act includes an obligation to make products invented with federal funds 'available to the public on reasonable terms.'"

      Kenny Stancil
      Mar 23, 2023

      Two days after President Joe Biden's administration rejected a petition asking federal regulators to use their authority to lower the astronomical price of a lifesaving prostate cancer drug developed entirely with public funds, petitioners on Thursday filed an administrative appeal.

      At issue is enzalutamide, a drug the Japanese pharmaceutical giant Astellas and its U.S. counterpart Pfizer sell under the brand name Xtandi. Although Xtandi owes its existence to U.S. taxpayers, who bankrolled 100% of its development, an annual supply of the drug costs $189,900 in the United States—three to six times more than its list price in other wealthy nations.

      Keep ReadingShow Less
      News
      Big Pharma
      drug pricing

      'Appalling': Biden Administration Declines to Force Big Pharma to Cut Price of Prostate Cancer Drug

      "This decision effectively rubber-stamps continued Big Pharma abuse," said one Democratic lawmaker.

      Brett Wilkins
      Mar 21, 2023

      Patient advocates on Tuesday blasted the Biden administration's refusal to compel the manufacturer of a lifesaving prostate cancer drug developed completely with public funds to lower its nearly $190,000 annual price tag.

      In 2021, prostate cancer patient Eric Sawyer petitioned U.S. Health and Human Services (HHS) Secretary Xavier Becerra to grant march-in rights—under which the government can grant patent licenses to companies other than a drug's manufacturer—for enzalutamide, which is sold under the brand name Xtandi by Pfizer and Japanese pharmaceutical giant Astellas.

      Keep ReadingShow Less
      News
      Big Pharma
      SIGN UP FOR OUR NEWSLETTER
      Quality journalism. Progressive values. Direct to your inbox.
      Follow Us
      Most Popular

      House GOP Unveils Budget With Trillions in Cuts to Medicaid, Food Benefits, and More

      Auto Giants Refusing Union Demands Paid Just 1% in Federal Taxes on $42 Billion in Profits: Analysis

      Proposed Budget Offers Horrifying Vision of What Republicans Would Do If They Could

      Demanding an End to 'Deadly Fossil Fuels,' Tens of Thousands Take the Streets in NYC

      AOC Says Climate Movement Must Become 'Too Big and Too Radical to Ignore'

      Progressives Slam House GOP Push for Social Security 'Death Panel'

      With Alito's Billionaire Patron Holding $90 Million in Finance Firms, Watchdog Demands Recusal From CFPB Case

      Study Finds 'Forever Chemical' Exposure Increases Risk of Certain Cancers in Women

      Trump's Viciously Anti-Worker Record in the Spotlight Ahead of Detroit Trip

      Libya Dam Disaster Shows Horrific Consequences of US/NATO Imperialism

      Independent, nonprofit journalism needs your help.
      Please Pitch In
      Today!